Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.50 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.45 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.45 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.44 |
| ▸ | ESR2 known ✓ | Q92731 | 2/20 | 0.41 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.41 |
| ▸ | PRKCI known ✓ | P41743 | 1/20 | 0.41 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.40 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.40 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.40 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.40 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33713 | 0.97 | — | — | |
| SCHEMBL5571369 | 0.89 | CA1 (0.45) | CA1CA2PDE10AKDM4EHSD17B10 | |
| SCHEMBL31530730 | 0.77 | — | — | |
| SCHEMBL470144 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL11546195 | 0.76 | CASP1 (0.56) | CA1CA2PDE10AKDM4EHSD17B10 | |
| Bromide SCHEMBL2856203 | 0.75 | CA3 (0.54) | CA1CA2PDE10AKDM4EHSD17B10 | |
| 2,4-Diaminophenol SCHEMBL456211 | 0.74 | ALDH1A1 (0.54) | CA1CA2PDE10AKDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL8645112 | 0.74 | ALDH1A1 (0.59) | CA1CA2HSD17B10TDP1ALOX15 | |
| 2,4-Diaminophenol SCHEMBL1884352 | 0.74 | ALDH1A1 (0.54) | CA1CA2PDE10AKDM4EHSD17B10 | |
| 2,4-Diaminophenol SCHEMBL7221197 | 0.74 | ALDH1A1 (0.54) | CA1CA2PDE10AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728063-A | Treatment of cancer with anti-OX 40 antibodies and multiple kinase inhibitors | 百济神州有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114450025-A | Treatment of cancer using a combination comprising multiple tyrosine kinase inhibitors and immune checkpoint inhibitors | 百济神州有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-104876941-B | Fused tricyclic class compound and its application | 南京汇诚制药有限公司 | 2019-02-01 | — | — | CN | disclosed |
| CN-104876941-A | Fused tricyclic compound and applications thereof | NANJING SANHOME PHARMACEUTICAL CO LTD | 2015-09-02 | — | — | CN | disclosed |
| CN-103025740-B | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | METHYLGENE INC | 2015-07-01 | — | — | CN | disclosed |
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| US-8455484-B2 | Selected inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-06-04 | — | — | US | disclosed |
| CN-103025740-A | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | METHYLGENE INC | 2013-04-03 | — | — | CN | disclosed |
| EP-2563795-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | MethylGene Inc. (CA) | 2013-03-06 | — | — | EP | disclosed |
| EP-2563794-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY AND USE THEREOF TO TREAT OPHTHALMIC DISORDERS | MethylGene Inc. (CA) | 2013-03-06 | — | — | EP | disclosed |
| CN-102947315-A | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC | 2013-02-27 | — | — | CN | disclosed |
| WO-2011127565-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY AND USE THEREOF TO TREAT OPHTHALMIC DISORDERS | METHYLGENE INC. (CA) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011127567-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110257175-A1 | Selected Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| EP-0901499-B1 | ADENOSINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2002-04-10 | — | — | EP | disclosed |
| US-5998388-A | N6-PHENYL-SUBSTITUTED | GLAXO WELLCOME INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0901499-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043300-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ERBB2, ABL1, FLT1 | CA2 1217/4885PTGS2 1613/4885KDR 5/4885 |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | FLT1, KDR, FLT4 | CA2 1084/4885PTGS2 1192/4885KDR 2/4885 |
| US-20110257175-A1 | Selected Inhibitors of Protein Tyrosine Kinase Activity | ABL1, PRKDC, PRKACA | CA2 1007/4885PTGS2 2194/4885KDR 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.